<DOC>
	<DOCNO>NCT01559090</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics pharmacodynamics MEDI-546 Japanese SLE patient .</brief_summary>
	<brief_title>Safety Tolerability Intravenous Dose MEDI-546 Japanese Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>A phase 2 , multicenter , open-label , dose-escalation study evaluate safety tolerability intravenous dose MEDI-546 , human monoclonal antibody direct type I interferon receptor ( IFNAR ) , Japanese subject active systemic lupus erythematosus ( SLE )</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Fulfils least 4 11 American College Rheumatology ( ACR ) classification criterion SLE . Weight great equal 40.0 kg . Diagnosis pediatric adult SLE chronic disease activity require ongoing treatment observation â‰¥ 24 week prior screen . Currently receive stable dose oral prednisone and/or antimalarials/immunosuppressives . Active moderate severe SLE disease base SLE disease activity score . Active severe unstable neuropsychiatric SLE . Active severe SLEdriven renal disease unstable renal disease . Clinically significant active infection include ongoing chronic infection . Known history primary immunodeficiency underlie condition human immunodeficiency virus infection splenectomy predisposes subject infection . Confirmed positive test hepatitis B positive test hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Japan</keyword>
	<keyword>Phase2</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>SLE , MEDI-546</keyword>
</DOC>